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Summary
Background We previously showed that human anti-T-lymphocyte globulin (ATLG) plus ciclosporin and methotrexate 
given to patients with acute leukaemia in remission, having allogeneic haemopoietic stem-cell transplantation with 
peripheral blood stem cells from an HLA-identical sibling donor after myeloablative conditioning, significantly 
reduced 2-year chronic graft-versus-host disease (cGVHD) incidence and severity, without increasing disease relapse 
and infections, and improves cGVHD-free and relapse-free survival (cGRFS). The aim of an extended follow-up study 
was the assessment of long-term outcomes, which are, in this context, scarcely reported in the literature. We report 
unpublished data on quality of life (QoL) from the original study and the results of a follow-up extension. 
Methods In the original open-label study, patients with acute myeloid and lymphoblastic leukaemia in first or subsequent 
remission, having sibling HLA-identical allogeneic peripheral blood stem-cell transplantation, were randomly assigned 
(1:1) to receive ATLG plus standard GVHD prophylaxis with ciclosporin and short-term methotrexate (ATLG group) or 
standard GVHD prophylaxis without ATLG (non-ATLG group). Conditioning regimens were cyclophosphamide 
120 mg/kg with either total body irradiation (12 Gy) or busulfan (12·8 mg/kg intravenously or 16 mg/kg orally), with or 
without etoposide (30–60 mg/kg). Randomisation was stratified according to centre and disease risk. The primary 
endpoint was cumulative incidence of cGVHD at 2 years. The primary and secondary endpoints, excluding QoL, have 
been published. QoL, assessed using European Organisation for Research and Treatment of Cancer QLQ-C30 and 
QLQ-HDC29 questionnaires, was an unpublished secondary endpoint, which we now report here. A follow-up extension 
was then done, with the primary endpoint cumulative incidence of cGVHD. Enrolment has been completed for both 
studies. The original trial (number, NCT00678275) and follow-up extension (number, NCT03042676) are registered at 
ClinicalTrials.gov. 
Findings In the original study, from Dec 14, 2006, to Feb 2, 2012, 161 patients were enrolled and 155 were randomly 
assigned to either the ATLG group (n=83) or to the non-ATLG group (n=72). In the follow-up study, which started on 
Feb 7, 2017, and was completed on June 30, 2017, 61 patients were included in the ATLG group and 53 were included in 
the non-ATLG group. Global health status showed a more favourable time course in the ATLG group compared with the 
non-ATLG group (p=0·02; treatment by visit interaction). ATLG was descriptively superior to non-ATLG at 24 months 
for physical function (points estimate –14·8 [95% CI –26·4 to –3·1]; p=0·014) and social function (–19·1 [–38·0 to –0·2]; 
p=0·047), gastrointestinal side-effects (8·8 [2·5–15·1]; p=0·008) and effect on family (13·5 [1·2–25·8]; p=0·032). 
Extended follow-up (median 5·9 years [IQR 1·7–7·9]) confirmed a lower 5-year cGVHD incidence (30·0% [95% CI 
21·4–41·9] vs 69·1% [59·1–80·1]; analysis for entire follow-up, p<0·001), no increase in relapses (35·4% [26·4–47·5] vs 
22·5% [14·6–34·7]; p=0·09), improved cGRFS (34·3% [24·2–44·5] vs 13·9% [7·1–22·9]; p=0·005), and fewer patients 
still in immunosuppression (9·6% vs 28·3%; p=0·017) in the ATLG group compared with the non-ATLG group. 5-year 
overall survival, relapse-free survival, and non-relapse mortality did not differ significantly between groups.
Interpretation The addition of ATLG to standard GVHD prophylaxis improves the probability of surviving without 
disease relapse and cGVHD after myeloablative peripheral blood stem-cell transplantation from an HLA-identical 
sibling donor for patients with acute leukaemia in remission. Further additional benefits are better QoL and shorter 
immunosuppressive treatment compared with standard GVHD prophylaxis without ATLG. Therefore, in this setting, 
ATLG plus standard GVHD prophylaxis should be preferred over the standard GVHD prophylaxis alone.
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Research in context
Evidence before this study
We searched PubMed for articles published between 
Jan 1, 2000, and July 12, 2018, using the search terms 
“antilymphocyte globulin” AND “graft versus host disease 
prevention” AND “randomized” and filtered for clinical trials. 
We identified three prospective randomised trials on unrelated 
donor transplants and only one on HLA-identical sibling 
transplants. The first trial, published 9 years ago, showed that 
the addition of 60 mg/kg of anti-T-lymphocyte globulin (ATLG) 
to standard graft-versus-host disease (GVHD) prophylaxis (with 
ciclosporin and methotrexate), after a myeloablative regimen 
in patients transplanted from unrelated donors for their 
haematological malignancies, reduced the incidence of acute 
GVHD and chronic GVHD (cGVHD) without increasing relapse or 
non-relapse mortality. Overall survival and disease-free survival 
were not significantly different in the two groups  (60 mg/kg 
ALTG vs standard prophylaxis). An increased incidence of 
cytomegalovirus and Epstein-Barr virus reactivations were 
recorded. The study was updated in 2017, and after a median 
follow up of 8·6 years, the results reported in the original study 
analysis were supported in the long term, showing a significant 
increase in the composite endpoint (severe GVHD-free and 
relapse-free survival [cGRFS]) from 13% to 34% after 8 years 
from transplant. The second trial used the same ATLG dose and 
schedule as the first study in patients with acute leukaemia in 
remission, with myelodysplastic syndromes with 10% or less 
bone marrow blasts, and who had a transplant from an 
unrelated donor after a myeloablative conditioning regimen. 
The addition of ATLG to standard GVHD prophylaxis (ATLG 
group) did not improve moderate-to-severe cGVHD-free 
survival, the primary endpoint, compared with standard 
GVHD prophylaxis (non-ATLG group). Incidence of 
moderate-to-severe cGVHD was significantly lower in the ATLG 
group than in the non-ATLG group, but progression-free 
survival and overall survival were lower in the non-ATLG group. 
Moderate-to-severe cGRFS, which was the primary endpoint of 
the study, was not different in the two groups. The third trial we 
identified focused on patients with high-risk acute myeloid 
leukaemia who were in remission after receiving a 
myeloablative transplant from an unrelated donor in a 
paediatric setting. Patients were randomly assigned to receive 
either ATLG 30 mg/kg or 15 mg/kg. Patients in the 15 mg/kg 
group had a significant increase in overall survival and 
event-free survival compared with the 30 mg/kg group due to a 
reduced incidence of lethal viral infections while maintaining 
the same effect on GVHD prevention. Finally, the only trial that 
focused on HLA-identical sibling transplants was published by 
our group in 2016. The addition of ATLG to standard GVHD 
prophylaxis in patients with acute leukaemia in remission, who 
had peripheral blood stem-cell myeloablative transplants from 
HLA-identical sibling donors, significantly decreased the 
incidence and severity of cGVHD without a negative effect on 
survival, relapse, and non-relapse mortality at 2 years. 
Accordingly, cGRFS increased with the addition of ATLG 
(16·8% in the non-ATLG group vs 36·6% in the ATLG group at 
2 years from transplant). No quality-of-life (QoL) data were 
reported in any of the randomised studies examined.
Added value of this study
This study provides two important added values. First, we 
report QoL data on the only randomised study that focused on 
sibling transplants, and show that even after adjusting for 
confounding factors, such as age, sex, country, and GVHD, 
patients in the ATLG group showed a better QoL than those in 
the non-ATLG group (standard GVHD prophylaxis with 
ciclosporin and methotrexate). In particular, global health 
status scoring was higher, with a more pronounced 
improvement over time, in the ATLG group (p=0·02): 
the treatment group marginal mean difference was 2·8 points 
(SEM 3·9) at day 100 and increased to 10·5 points (5·3) at 
24 months, in favour of ATLG. Second, after an extended follow 
up (median 5·9 years [IQR 1·7–7·9]), we observed a reduction 
in GVHD incidence in the long term (30·0% [95% CI 21·4–41·9] 
in the ATLG group vs 69·1% [59·1–80·1] in the non-ATLG group 
at 5 years; p<0·001) and an improvement of 5-year cGRFS 
(34·3% [95% CI 24·2–44·5] vs 13·9% [7·1–22·9]; p=0·005) in the 
ATLG group compared with the non-ATLG group. Time to 
permanent discontinuation of immunosuppression was also 
significantly shortened with ATLG administration (median 
6·9 months vs 19·9 months; p=0·010). Finally, although no 
improvement in overall survival was shown in the ATLG group, 
relapse incidence and relapse-free survival were not affected by 
its addition to standard GVHD prophylaxis.
Implications of all the available evidence
The results from this study will be helpful in clinical counselling 
of the risk of cGVHD after HLA-identical sibling peripheral blood 
stem-cell myeloablative transplantation for patients with acute 
leukaemia in remission. This risk can be reduced without a 
significant increase in relapse risk compared with ciclosporin 
and methotrexate. Additionally, the QoL is significantly 
improved and patients could therefore be further reassured. 
For these reasons, the addition of ATLG to the standard GVHD 
prevention with ciclosporin and methotrexate could be the 
preferred combination for GVHD prophylaxis in this setting. 
The role of ATLG in different settings of transplantation 
(eg, after a reduced intensity conditioning, with a different 
stem-cell source, or with more advanced diseases) needs to be 
further investigated.
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Introduction
Chronic graft-versus-host disease (cGVHD) is one of the 
major complications after allogeneic haemopoietic stem-
cell transplantation, especially when peripheral blood 
stem cells are used.1,2 Previous acute GVHD (aGVHD), 
age, sex mismatch, and the use of peripheral blood stem 
cells as stem-cell source are well recognised risk factors 
of cGVHD occurrence. Peripheral blood stem cells have 
become the most frequently used stem-cell source for 
allogeneic transplants,3,4 even though this source has 
been associated with a higher incidence of cGVHD in 
transplants with both unrelated and sibling donors.1,2,4 
cGVHD, in particular the extensive type, has a significant 
effect on non-relapse mortality, morbidity, and quality of 
life (QoL).5,6 A new composite endpoint (cGVHD-free 
and relapse-free survival [cGRFS]) has been increasingly 
used to measure the outcome of the transplant procedure 
by assessing cGVHD-free and relapse-free survival.7,8 For 
these reasons, several attempts to improve the efficacy of 
GVHD prophylaxis are being made, in particular with 
the aim of reducing incidence  and severity of cGVHD. 
Different preparations of rabbit anti-T-cell globulins are 
available and have been tested as in-vivo T-cell depletion. 
Human anti-T-lymphocyte globulin (ATLG) was prepared 
by immunisation of rabbits with a Jurkat cell line, and 
anti-thymocyte globulin (ATG) was obtained in rabbits 
against human thymocytes. 
Several randomised studies have already shown that 
the addition of ATLG or ATG to the standard GVHD 
prophylaxis with a calcineurin inhibitor and methotrexate 
given to patients having myeloablative transplants from 
unrelated donors reduces both aGVHD and cGVHD 
incidence without increasing the relapse risk,9–11 with the 
exception of one study,12 and improves cGRFS. However, 
in the case of sibling transplantation the only available 
randomised study13 showed that ATLG, given at 10 mg/kg 
once daily 3 days to 1 day before  myeloablative sibling 
transplants for patients with acute leukaemia in 
remission, reduced the cumulative incidence of cGVHD 
from 68·7% to 32·2% at 2 years, without increasing 
relapse incidence or infectious complications. Overall 
survival and relapse-free survival in this study were not 
affected by the addition of ATLG, whereas cGRFS 
significantly improved from 16·8% to 36·6% at 2 years.
Here, we report unpublished data on QoL from the 
original study and the results of a follow-up extension, 
with the aim of assessing the main outcomes (cGVHD 
incidence, relapse risk, non-relapse mortality, overall 
survival, disease-free survival, and cGRFS), recording new 
cases of cGVHD, and assessing immunosuppression 
discontinuation, secondary malignancies, and occupational 
status after transplantation.
Methods
Study design and participants
The multicentre, open-label, phase 3 ATGFamilyStudy,13 
was run in Italy (16 haemopoietic stem-cell transplant 
programmes), Spain (six), Germany (three), and Israel 
(one; appendix). Patients with acute leukaemia in 
complete remission were randomly allocated (1:1) to 
receive ATLG plus the standard regimen of ciclosporin 
and methotrexate after a myeloablative conditioning 
regimen or the standard regimen alone. The myeloablative 
conditioning regimen consisted of cyclophosphamide 
(120 mg/kg) and total-body irradiation (12 Gy) or busulfan 
(16 mg/kg orally or 12·8 mg/kg intravenously), with 
or without etoposide (30–60 mg/kg). Allogeneic 
transplantations were performed from an HLA-identical 
sibling (8/8 matched) donating peripheral blood stem 
cells. Eligible patients were aged 18–65 years, had acute 
myeloid or lymphoblastic leukaemia, with adequate 
organ function, and were in first or subsequent complete 
cytological remission. All patients were admitted to the 
hospital for transplantation; there was no central review 
of diagnosis. Treatment of GVHD was given according to 
centre policy. Full details about the design, conduct, 
analysis, and results of the original study have been 
previously published.13
During the 2-year ATGFamilyStudy, QoL was assessed 
by means of two European Organisation for Research and 
Treatment of Cancer (EORTC) questionnaires—namely, 
the QLQ-C30, which has been developed for patients with 
cancer, including the setting of haemopoietic stem-cell 
transplantation,14 and the QLQ-HDC29 for those having 
intensive chemotherapy (version 3.0).15 For the long-term 
study, all the patients randomly assigned in the original 
study and who provided written informed consent were 
considered eligible.
The original study was approved by each competent local 
ethics committee, according to the Declaration of Helsinki, 
and both studies are registered with ClinicalTrials.gov 
(NCT00678275 for QoL [the original trial] and NCT03042676 
for the extended follow-up).
Randomisation and masking
Patients were randomly assigned 1:1, with stratification 
according to centre and disease risk. The randomisation 
was unmasked. The randomisation code was generated 
by nQuery Advisor, version 6.0, with the use of a 
permuted, block-randomisation plan and a block size 
of 4. Further details have been previously published.13
Procedures
All patients received ciclosporin, which was started the 
day before transplantation (day –1) with the aim of 
obtaining a trough plasma concentration of 200 ng/mL 
or higher, in combination with methotrexate at a dose of 
15 mg/m² daily on day 1 and then 10 mg/m² on days 3, 
6, and 11 after transplantation. The study protocol 
recommended that ciclosporin should be tapered 
around day 120 in the absence of aGVHD (25% every 
2 weeks) and discontinued at day 180, provided that 
there was no evidence of GVHD. ATLG (Grafalon, 
NEOVII Biotech, Gräfelfing, Germany), was given at a 
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dose of 10 mg/kg once daily from day –3 to day –1 before 
transplantation.
The QLQ-C30 includes one global health status scale, 
five functional scales (physical, role, emotional, 
cognitive, and social functioning), and nine symptom 
scales (fatigue, nausea or vomiting, pain, dyspnoea, 
insomnia, appetite loss, constipation, diarrhoea, and 
financial problems). The QLQ-HDC29 is  composed of 
14 symptom scales (gastrointestinal side-effects, worries 
or anxiety, effect on family, body image, sexuality, 
inpatient issues, skin problems, fever or chills, urinary 
frequency, aches or pain in bones, taking regular drugs, 
finishing things, ability to have children, and experience 
helping to distinguish what is important in life). For the 
global health status scale and the functional scales of the 
QLQ-C30, higher scores indicate better QoL, whereas for 
the symptom scales of both question naires, higher 
scores indicate more pronounced im pairment of QoL. 
The administration of question naires was at admission 
in hospital, at 3–6 to 12–24 months after transplantation.
After the end of the main study, follow-up information 
was requested for all eligible patients during 2017 
(February–June, 2017). For each patient the variables 
recorded were date, disease, and survival status at last 
contact, new cGVHD episodes or flares of previous 
cGVHD, immunosuppressive medication, occupational 
status, and appearance of secondary malignancies. 
cGVHD staging was done according to the modified 
Seattle criteria, as stated in the protocol, and cumulative 
incidence was calculated accordingly.
Outcomes
The primary endpoint of the original study was 2-year 
cumulative incidence of cGVHD; the predefined secondary 
endpoints included the incidences of engraftment, 
aGVHD, non-relapse mortality, relapse-free survival, 
overall survival, cGRFS, infectious complications, and QoL 
according to the EORTC QLQ-C30 and QLQ-HDC29 
questionnaires at 2 years. The results of all outcomes 
except QoL have been previously published.13 The primary 
objective of the follow-up study was the establishment of 
an electronic database including variables capturing the 
update of cGVHD, survival, disease relapse, immuno-
suppressive therapy, and the eventual recovery of working 
activity. Hence, similar to the original study, cGVHD 
incidence, overall survival, relapse-free survival, cGRFS, 
non-relapse mortality, relapse incidence, and immuno-
suppression withdrawal at 5 years were assessed as 
secondary outcomes and cumulative incidence of cGVHD 
was the primary outcome of the follow-up study. No long-
term follow-ups of QoL, infections, and toxicity were done.
Statistical analysis
We assessed cGVHD, cGRFS, relapse, and non-relapse 
mortality by cumulative incidence analysis.16 We counted 
cGRFS, relapse or progression, and cGVHD of any kind 
as events. Competing risks were death or relapse for 
cGvHD, cGvHD and relapse-free death for cGRFS, non-
relapse death for relapse, and relapse for non-relapse 
mortality. We compared treatment groups using Gray’s 
test. We assessed overall survival and relapse-free survival 
by Kaplan-Meier analysis with 95% CIs based on a 
transformation of intervals for the log-minus-log survival 
function and using log-rank tests to compare the 
treatment groups.
We did further treatment group comparisons with the 
use of χ² tests for nominal data, Mann-Whitney U tests 
for ordinal data, and analyses of variance for interval or 
ratio-scale data. We used exploratory Cox multiple 
regression analysis for determining the confounding 
effect of recipient age, first versus second remission, 
acute lymphoblastic versus acute myeloid leukaemia, 
cytogenetic risk, donor or recipient sex mismatch, 
recipient cytomegalovirus seropositivity, type of 
conditioning, CD34+ cells transplanted, and grade of 
aGVHD and cGVHD (grade of cGVHD as time 
dependent variable because it was assumed that cGVHD 
might modify the risk of relapse and mortality) on the 
incidence of cGVHD, non-relapse mortality, relapse, 
relapse-free survival, and overall survival in addition to 
the effect of treatment (ATLG vs non-ATLG). We used 
forced entry for treatment and backward elimination for 
all other covariates.
For the investigation of QoL, we used mixed models for 
repeated measures and linear mixed models to analyse 
the time courses and the slopes of the outcomes 
depending on treatment group (ATLG vs non-ATLG), 
age, country, sex, and cGVHD. In particular, we did 
mixed models for repeated measures analyses for testing 
whether the independent variables and the specified 
interactions between them had a significant influence on 
the scores of the QLQ-C30 and QLQ-HDC29 scales and 
Figure 1: Trial profile
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their changes over time. We tested treatment group 
differences at particular visits using contrasts. We used 
linear mixed models analyses to investigate whether the 
groups defined by the independent variable(s) differed 
with regard to the slopes of the time course of the 
QLQ-C30 or QLQ-HDC29 scales.
For both mixed models for repeated measures and linear 
mixed models analyses, we fitted models using restricted 
maximum likelihood parameter estimation, an unstructured 
covariance matrix, and the Satterthwaite approximation for 
determining the degrees of freedom. Analyses were based 
on the assumption that data were missing at random—
ie, missingness might have depended on observed data 
but not on unobserved data. To assess the robustness of 
the missing at random assumption, we did sensitivity 
analyses using multiple imputation and imposing different 
penalties on missing data in the ATLG group but not in the 
non-ATLG group. For global health status or QoL, we 
imposed penalties between 0·5 and 2·5 points.
All analyses were based on all patients analysed for 
safety and efficacy in the original 2-year study,13 unless 
otherwise noted. All p values are two-sided and are to be 
interpreted descriptively (the term significant is used to 
characterise p values ≤0·05 and is not intended in 
a confirmatory sense). For time-to-event analyses, 
the reported p values apply to the comparison of the 
cumulative incidence or survival curves across the 
entire follow-up. All analyses based on events occurring 
later than 24 months after stem-cell transplantation 
are to be considered post-hoc analyses. For statistical 
analyses we used NCSS version 10 for cumulative 
incidence analysis and IBM SPSS Statistics version 24 
for all other analyses.
Role of the funding source
The study was an academic study. The study was 
supported by the European Society for Blood and Marrow 
Transplantation (EBMT) as an EBMT-labelled study of 
the Chronic Malignancies Working Party. Neovii Biotech 
supplied the drug for free and provided  financial support 
to NK. Neither EMBT nor Neovii Biotech had a role in 
study design, data collection, data analysis and data 
interpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and had 
the final responsibility for the decision to submit for 
publication.
Results
Between Dec 14, 2006, and Feb 2, 2012, 161 patients were 
enrolled, and six patients were excluded because of donor 
refusal or disease progression. 155 patients were 
randomly assigned to each group (n=83 in the ATLG 
group; n=72 in the non-ATLG group) and were included 
in the full analysis set. The final analysis was performed 
after the last patient achieved at least a 2-year observation 
(June 8, 2014). 119 (77%) of 155 patients were alive at the 
end of the study. The extension study started on 
Feb 7, 2017, and all the follow-up information was 
returned and completed by June 30, 2017, for all patients. 
114 patients entered the follow-up study, 61 in the ATLG 
group and 53 in the non-ATLG group. 12 patients died in 
the ATLG group and 10 patients died in the non-ATLG 
group. One patient was lost to observation during the 
follow-up study and finally 48 patients in the ATLG group 
and 43 patients in the non-ATLG group were confirmed 
to be alive at the end of the follow-up on June 30, 2017 
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(figure 1). The median observation time from 
transplantation was 5·9 years (IQR 1·7–7·9).
According to the protocol, QoL forms were to be 
completed at five visits. On the assumption that all 
155 patients eligible for the full analysis set would have 
completed the trial as scheduled, a total of 775 QoL forms 
would have been expected. However, 347 (45%) forms 
were actually retrieved, 98 (13%) forms were missing 
because the applicable visit was not completed (because of 
premature withdrawal or because the patient had missed 
an interim visit), and 330 (43%) forms were missing even 
though the patient had attended the applicable visit. 
37 (24%) of 155 patients did not provide any QoL data, of 
whom ten were from the single participating centre in 
Israel, where QoL was not assessed.
Across all visits, the proportion of forms actually 
retrieved compared with the number that could have been 
completed, given the observed visit attendance, was 
similar between groups (50% in the ATLG group and 53% 
in the non-ATLG group). Based on actual visit attendance, 
the proportion of returned QoL forms decreased by visit 
(108 [70%] of 155 patients before stem-cell transplantation; 
70 [48%] of 145 patients at 100 days, and 45 [41%] of 
110 patients at 24 months after stem-cell transplantation). 
41 (49%) of 83 patients in the ATLG group and 43 (60%) of 
72 patients in the non-ATLG group provided any QoL 
forms after stem-cell transplantation. Centre was the 
variable with the closest association with availability of 
QoL forms: of 26 centres contributing any patients to the 
full analysis set, six had QoL form return rates between 
75% and 100% relative to the actual visits, whereas eight 
had return rates between 0% and 25% (not counting the 
Israeli centre). Within centres, QoL form retrieval and the 
type of treatment received had no apparent association.
No systematic association was found between age and 
QoL form return. In both treatment groups women 
tended to be more inclined than men to complete their 
QoL forms (55% vs 47% of expected forms in the ATLG 
group; 57% vs 42% in the non-ATLG group). Patients 
with acute lymphoblastic leukaemia tended to return 
slightly more forms than those with acute myeloid 
leukaemia (57% vs 47% in the ATLG group; 63% vs 49% 
in the non-ATLG group). In the ATLG group, the 
presence or absence of cGVHD was not associated with 
QoL form return (50% vs 51%), whereas a slightly higher 
return rate was observed for patients with cGVHD in the 
non-ATLG group (57% vs 46%).
Most subscales of the QLQ-C30 indicated an average 
improvement in QoL and reduction of symptoms over 
time, notably in the ATLG group. In a mixed models for 
repeated measures model controlling for country, age, 
sex, and cGVHD, patients in the ATLG group showed 
significantly more pronounced improvement in global 
health status or QoL over time compared with patients in 
the non-ATLG group (p=0·02), with a marginal mean 
treatment group difference of 2·8 points  (SEM 3·9) at 
day 100 and increasing to 10·5 points (5·3) at 24 months 
in favour of ATLG (figure 2A). Sensitivity analyses 
showed that superiority of ATLG was still seen despite a 
penalty of 2·5 points on all missing data points in the 
ATLG group, the largest penalty tested.
Beneficial effects of ATLG (p≤0·05) were also observed 
for four of the five functional scales comparing the 
treatment groups across the entire trajectory of time 
from the start of the study to the end (24 months); 
whereas comparing them at a particular time (month 24), 
the differences were significant only for physical (points 
estimate –14·8 [95% CI –26·4 to –3·1]; p=0·014) and 
social (–19·1 [–38·0 to –0·2]; p=0·047) functioning 
Figure 3: Cumulative incidence of cGVHD according to treatment group
(A) Overall cGVHD incidence. (B) Extensive cGVHD incidence. ATLG=anti-T-lymphocyte globulin. cGVHD=chronic 
graft-versus-host disease. The dashed line represents the timepoint of the analysis in the original study. The large 
arrows represent 5-year estimates.
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(figure 2B). Finally for QLQ-HDC29, only the two 
symptom scales were reported in the analysis and they 
are gastrointestinal side-effects (points estimate 8·8 
[95% CI 2·5–15·1]; p=0·008) and effect on family (13·5 
[1·2–25·8]; p=0·032; figure 2C).).
Linear mixed model analysis of QoL by country 
indicates that patients from Italy generally gave more 
favourable ratings for all functional scales and lower 
scores for most symptom scales than patients from 
Germany, whereas the time courses and slopes were 
similar for most scales (data not shown). Men and 
women showed similar QoL ratings at before and after 
haemopoietic stem-cell transplantation. Patients aged up 
to 34 years tended to provide more favourable functional 
ratings, less severe symptom scores, and showed more 
pronounced improvements of QoL than older patients 
(data not shown).
In the follow-up extension study, the 5-year cumulative 
incidence of overall cGVHD was 30·0% (95% CI 
21·4–41·9) in the ATLG group versus 69·1% (59·1–80·1; 
p<0·001) in the non-ATLG group and for extensive 
cGVHD was 6·2% (2·7–14·5) in the ATLG group versus 
38·2% (28·4–51·3; p<0·001) in the non-ATLG group 
(figure 3A, 3B). Two new episodes of cGVHD occurred in 
the ATLG group beyond 2 years (both limited, one patient 
had already been counted as a case of cGVHD in our 
Figure 4: Non-relapse mortality (A), relapse or progression (B), overall survival (C), and relapse or progrssion-free survival (D) according to treatment group
ATLG=anti-T-lymphocyte globulin. The dashed lines represent the time point of the analysis in the original study. The large arrows represent 5-year estimates. 
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original 2-year analysis13 but was then changed to a 
post-2-year case after obtaining a correction of the onset 
date from the centre) and three in the non-ATLG group 
(two limited and one extensive). Moreover, three patients 
in the non-ATLG group with limited cGVHD during the 
main study had an extensive episode during follow-up, 
compared with none in the ATLG group. Five (10%) of 
52 patients in the ATLG group who provided any data 
during follow-up were still under immunosuppression at 
last contact during follow-up compared with 13 (28%) of 
46 patients in the non-ATLG group (p=0·017), conveying 
a shorter median time to permanent discontinuation of 
immunosuppression (6·9 months [IQR 6·1–13·2] in the 
ATLG group vs 19·9 months [8·3–36·2] in the non-ATLG 
group; p=0·010).
Cox regression analysis showed that ATLG administration 
(hazard ratio [HR] 0·35 [95% CI 0·21–0·61]; p< 0·001), sex 
mismatch (female donor to male recipient; 1·89 
[1·05–3·40]; p=0·034), and previous aGVHD (1·57 
[1·26–1·96]; p< 0·001) were significant prognostic factors 
for cGVHD (table). The 5-year non-relapse mortality 
(figure 4A) and relapse incidence (figure 4B) were not 
significantly different between the two groups (5-year non-
relapse mortality, 9·8% [95% CI 5·1–18·9] in the ATLG 
group vs 14·4% [8·1–25·5] in the non-ATLG group; p=0·24; 
and 5-year relapse incidence, 35·4% [26·4–47·5] and 
22·5% [14·6–34·7]; p=0·09).
Cox regression analysis revealed that cGVHD was the 
most significant predictor for non-relapse mortality 
(HR 2·85 [95% CI 1·00–8·14]; p=0·051), followed by 
recipient age (in years) (1·04 [1·00–1·08]; p=0·066), 
whereas for relapse incidence the most significant 
predictors were type of pretransplant remission 
(0·32 [0·16–0·87]; p=0·026) and cytogenetic risk profile 
(1·84 [0·93–3·62]; p=0·080). ATLG administration did not 
significantly affect non-relapse mortality (0·79 [0·34–1·83]; 
p=0·583) or relapse incidence (1·47 [0·74–2·89]; p=0·270) 
(table).
The 5-year overall survival (figure 4C) was 64·5% 
(95% CI 53·1–73·0) in the ATLG group versus 70·2% 
(58·0–79·5; p=0·56) in the non-ALTG group. Relapse-free 
survival (figure 4D) was 54·8% (43·4–64·9) in the ATLG 
group versus 63·2% (50·1–73·2; p=0·32) in the non-ATLG 
group. 12 (20%) of 61 patients who entered follow-up in the 
ATLG group and 10 (19%) of 53 patients in the non-ATLG 
group died during the follow-up period after the end of the 
second year after stem-cell transplantation. Cox regression 
analysis of the follow-up results did not support the 
significant association between relapse-free survival and 
disease type (poorer survival for acute lymphoblastic 
leukaemia) reported in the original study; however, we 
found a significant adverse effect of high cytogenetic risk 
(HR 1·79 [95% CI 1·03–3·10]; p=0·039; table).
The composite endpoint cGRFS (figure 5) was 
significantly improved by ATLG administration, with a 
5-year estimate of 34·3% (95% CI 24·2–44·5) in the 
ATLG group versus 13·9% (7·1–22·9; p=0·005) in the 
non-ATLG group.
We recorded four cases of secondary malignancies; one 
in the ATLG group (squamous cell carcinoma of the 
mouth in a patient who developed limited mouth 
cGVHD after the end of the original study) and three in 
the non-ATLG group (relapse of a previous breast cancer 
p value Hazard ratio (95% CI)
cGVHD (–2 log likelihood=552·7; χ²=41·0; df=3; p<0·001)*
ATLG vs non-ATLG <0·001 0·35 (0·21–0·61)
Female donor, male recipient 0·034 1·89 (1·05–3·40)
aGvHD grade <0·001 1·57 (1·26–1·96)
Non-relapse mortality (–2 log likelihood=223·9; χ²=8·0; df=4; p=0·091)*
ATLG vs non-ATLG 0·583 0·79 (0·34–1·83)
Age, years 0·066 1·04 (1·00–1·08)
cGVHD 0·051 2·85 (1·00–8·14)
Remission 0·980 671 270·90 (0·00–IND)
Overall survival (–2 log likelihood=410·7; χ²=5·9; df=3; p=0·117)*
ATLG vs non-ATLG 0·491 0·81 (0·45–1·47)
Age, years 0·089 1·04 (1·00–1·06)
High vs low or intermediate cytogenetic risk 0·063 1·77 (0·97–3·24)
Relapse incidence (–2 log likelihood=336·6; χ²=7·5; df=3; p=0·0588)*
ATLG vs non-ATLG 0·270 1·47 (0·74–2·89)
First vs second remission 0·026 0·32 (0·16–0·87)
High vs low or intermediate cytogenetic risk 0·080 1·84 (0·93–3·62)
Relapse-free survival (–2 log likelihood=475·3; χ²=4·4; df=2; p=0·112)*
ATLG vs non-ATLG 0·662 0·89 (0·51–1·53)
High vs low or intermediate cytogenetic risk 0·039 1·79 (1·03–3·10)
aGVHD=acute graft-versus-host disease. ATLG=anti-T-lymphocyte globulin. cGVHD=chronic graft-versus-host disease. 
df=degrees of freedom. IND=indeterminate. *Omnibus test coefficients.
Table: Main results of multiple Cox regression models
Figure 5: Chronic graft-versus-host disease and relapse-free survival according to treatment group
cGVHD=chronic graft-versus-host disease. The dashed line represents the timepoint of the analysis in the original 
study. The large arrow represents 5-year estimate. 
Number at risk
(number censored)
ATLG
Non-ATLG
0
83 (0)
72 (0)
32 (1)
12 (0)
26 (3)
10 (0)
20 (8)
8 (2)
9 (19)
3 (7)
1 (28)
0 (10)
1 2 3 4 5 7 9 10 116 8
Time since stem-cell transplantation (years)
0
10
20
30
40
50
60
70
80
90
100
Re
la
ps
e,
 p
ro
gr
es
sio
n,
 o
r c
GV
H
D-
fre
e 
su
rv
iv
al
 (%
)
5-year survival
(24·2–44·5)
(7·1–22·9)
ATLG
Non-ATLG
Log-rank test p=0·005
34·3%
13·9%
Articles
www.thelancet.com/haematology   Vol 6   February 2019 e97
in a patient with limited cGVHD, and cervix and 
oesophageal cancers in patients affected by extensive 
cGVHD). Despite the significantly higher cGVHD 
incidence in the non-ATLG group, no appreciable 
difference was reported in the proportion of patients who 
returned to work (31 [60%] of 52 patients with valid data 
during follow-up in the ATLG group vs 26 [56%] of 
45 patients in the non-ATLG group; p=0·583).
Discussion
cGVHD is a major cause of late morbidity and mortality 
after allogeneic stem-cell transplantation.17 Additionally, 
cGVHD, especially in the more severe forms, is known to 
be associated with lower QoL.5,6,10 For these reasons, in the 
last years, much more attention has been given to QoL, 
and QoL measures are increasingly used as an indirect 
measure of efficacy in studies exploring new platforms for 
GVHD prophylaxis. Although mortality from cGVHD is 
decreasing nowadays because of better supportive care 
(including in particular anti-infectious therapies), 
deterioration of QoL is still one of the major concerns for 
patients having allogeneic haemopoietic stem-cell 
transplantation. In this study, we found that patients in the 
ATLG group showed a higher QoL score compared with 
those in the non-ATLG group. In particular, global health 
status was significantly better in the ATLG group with the 
treatment group difference increasing over time, as 
expected in a context of cGVHD, which takes time to 
develop and to affect organ function. Several additional 
QoL domains explored by QLQ-C30 and QLQ-HDC29, 
from physical, role, and emotional function to 
gastrointestinal side-effects and effect on family, favoured 
the ATLG group too. We also found differences in QoL 
scoring according to country (Italian patients gave QoL 
scoring associated with better status than German 
patients). It is not clear how to explain this finding: one 
hypothesis is that it could be related to the habits  and 
cultural environment, which are distinctive of each 
country. Cultural motivations are probably at the basis of 
the finding of no differences between the two groups in 
the proportion of patients going back to work after 
transplantation.
We previously showed13 in a randomised trial that the 
addition of ATLG to the standard GVHD prophylaxis, after 
a myeloablative conditioning peripheral blood stem-cell 
transplant from HLA-identical sibling donor for patients 
with acute leukaemia in remission, reduces the incidence 
and the severity of cGVHD without increasing relapses or 
infections. The cGVHD reduction was more pronounced 
for the extensive type of cGVHD. Our results support, in 
the long term, the observation that cGVHD is prominently 
reduced when ATLG is given. The reduction of cGVHD 
translated in fact into a lower proportion of patients still 
being under long-term immunosuppression medication at 
the last contact, and a shorter median time to permanent 
discontinuation of immunosuppression. ATLG infusion 
was the most important prognostic factor for cGVHD 
occurrence (table) and cGVHD is confirmed to be a 
predictive factor of non-relapse mortality, further 
underpinning the stringent need for effective GVHD 
prophylaxis to maintain low non-relapse mortality. These 
long-term results are consistent with those reported by 
Finke and colleagues18 in the setting of unrelated 
myeloablative conditioning transplants.
cGVHD itself, and its medications, can be expected to 
actively foster secondary malignancies because of 
reduction of cancer immune-surveillance, hence we 
evaluated the long-term development of secondary 
tumours, and found one case in the ATLG group and three 
in the non-ATLG group—all in patients with cGVHD. The 
overall incidence was low and thus no significant 
differences were shown, but no additional risks for 
neoplasms can be attributed to ATLG.
As an immunosuppressive drug, ATLG showed that it 
can increase infections and Epstein-Barr virus-associated 
lymphoproliferative disorders, at least in an unrelated 
setting in which higher doses are used. We previously 
showed13 that at the dose of 30 mg/kg in sibling 
myeloablative conditioning transplants, ATLG did not 
increase the incidence of Epstein-Barr virus-associated 
lymphoproliferative disorders, of cytomegalovirus, or of 
bacterial and fungal infections.
Although cGVHD reduction by ATLG is an obvious and 
recurrent effect that can be replicated in several settings 
with high dose range variation, the effect on relapse is 
more controversial. In myeloablative condition ing un-
related transplants, two randomised studies11,12 that used 
ATLG at the same doses showed a similar effect on 
reduction of aGVHD and cGVHD, but it had a discordant 
effect on relapse. Other randomised studies with different 
doses and timing of ATLG did not find an increase in 
relapses. In the setting of sibling myeloablative con-
ditioning transplants, a randomised study,13 and several 
retrospective analyses,19 were all in agreement about the 
absence of influence on relapses. Finally, in the setting of 
reduced intensity conditioning, caution for in-vivo T-cell 
depletion was suggested by an International Bone Marrow 
Transplant Registry study20 especially for advanced 
diseases, whereas for acute myeloid leukaemia in first 
remission, ATG or ATLG administration was not 
significantly associated with a higher relapse incidence.21 
Although most relapses after transplants for acute 
leukaemia occur within 2 years, we did not find a 
significant increase in relapses at 2 years or at 5 years in 
our study. However, in the abovementioned studies the 
most used polyclonal serum was anti thymocyte globulin 
(Thymoglobulin, Sanofi, Lyon, France) and not ATLG 
(Grafalon, NEOVII, Grafelfing, Germany), which is the 
one used in the present study. The two products differ in 
the manufacturing process, pulsed antigens, and antibody 
specificities; for this reason, conclusions drawn from 
studies with one preparation cannot be extrapolated to 
those with the other one. Relapse depends on several 
factors, such as disease phase, intensity of conditioning 
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regimen, type of transplant, and GVHD prophylaxis. 
ATLG is a polyclonal serum exerting its activity by 
depleting various cells of the immune system, such as 
T and B lymphocytes, by several mechanisms, including 
complement mediated lysis, antibody-dependent cell-
mediated cytotoxicity, increasing apoptosis, modulation of 
the function of cells involved in the migration phase of 
inflammation, interference with dendritic cells feature, 
and function and induction of T-cell regulatory cells.22,23
The number of lymphocytes might be crucial for the 
determination of the effectively active dose of ATLG, 
since these cells represent the major target of the drug. A 
pharmacokinetic or pharmacodynamic model suggests 
that the area under the curve of ATG is predictive 
of transplant outcome influencing the immune 
reconstitution, GVHD, and relapse probability.24 The 
pharmacokinetics can be predicted by the number of 
lymphocytes at the time of first ATG infusion, and the 
lymphocyte count has been proposed as criterion for 
ATG dosing instead of the standard per kg.25 A post-hoc 
analysis of the study reported by Soiffer and colleagues12 
found a significant association between lymphocyte 
count and outcome, and further studies are needed to 
support this intriguing hypothesis.
Unfortunately, we could not investigate any correlation 
between the number of lymphocytes and the outcome 
because the data were not captured in the case report 
forms of the ATGFamilyStudy. In the absence of a 
prospective, controlled study validating the pharm- 
acokinetic or pharmacodynamic approach, a general 
tendency to decrease the dose of ATLG is seen. In a 
randomised paediatric study,26 a lower dose of ATLG 
(15 mg/kg vs 30 mg/kg) resulted in an improved event-
free survival with maintenance of the anti-GVHD effect. 
In this analysis, with the limitation of the power of the 
study, relapse was not associated with ATLG infusion 
even with a longer observation period, whereas anti-
GVHD activity was clearly maintained. Several reasons 
explaining these findings could be hypothesised, such as 
the dose used in this trial, which was half of that used in 
the randomised studies on unrelated transplants, the 
preparing regimen, which was myeloablative, and the 
haematological disease in remission. Finally, a potential 
antileukaemic effect of ATLG cannot be excluded.27,28
The Cox regression analysis supports, as in our 
previous trial report,13 that the use of ATLG does not 
affect relapse risk, whereas it was clearly linked to the 
type of disease remission and to the disease risk—ie, the 
cytogenetic profile. In particular, the evidence that 
ATLG was not associated with increased relapse risk, 
specifically in higher risk subgroups, supports the use 
of ATLG in addition to the standard GVHD prophylaxis 
with ciclosporin and methotrexate as a new standard for 
GVHD prophylaxis in this transplantation setting.
Overall survival and relapse-free survival were not 
different in the two groups. The reasons why the 
conspicuous decrease in the occurrence of cGVHD, 
especially the extensive form, without a significant increase 
of relapse did not translate into a survival advantage cannot 
be fully explained. The long-lasting benefit of ATLG is 
further supported by the improved cGRFS we found in the 
original report and in the extended follow-up, reassuring 
patients about the actual success of transplantation.
This study has some limitations: first, in this analysis we 
have reported cGVHD incidence according to the Seattle 
modified classification, as stated in the protocol, because 
at the time of the study planning, the National Institutes 
of Health classification,29 although already published, was 
not yet standard for most transplant programmes in 
Europe. Second, the interpretation of the QoL is limited 
by the open-label design of the study, which could be 
particularly important for a patient-reported outcome, and 
is also limited by a substantial amount of missing data, 
which could introduce bias and could thus interfere with 
the robustness of the QoL findings. The results suggest, 
however, that missingness of QoL data was mainly 
associated with the observation of a clinical endpoint 
(death or relapse or progression), which caused premature 
study termination, or with deficiencies in patient 
management and QoL form retrieval at some of the 
participating centres, which occurred independently of 
the treatment received. Although the reasons for 
missingness could have inflicted some biases on the 
overall levels of the QoL scores produced from longitudinal 
modelling in mixed linear model analyses, it appears to be 
extremely improbable that they might have biased the 
comparisons between the treatment groups. Moreover, 
sensitivity analyses showed that the deviations from the 
missing at random assumptions underlying mixed linear 
modelling might not have been substantial. Third, it is 
important to note that all analyses based on data acquired 
more than 24 months after stem-cell transplantation had 
not been predefined in the original protocol of the 2-year 
study13 and are thus to be considered post-hoc analyses.
In conclusion, long-term observation of patients with 
acute leukaemia in remission given ATLG in the setting of 
HLA-identical sibling myeloablative peripheral blood 
stem-cell transplants supports the benefit of the addition 
of ATLG in terms of improved cGRFS and lower cGVHD 
incidence and severity, without increase of leukaemia 
relapse. Consequently, QoL was improved and over the 
years, the need for immunosuppression was reduced. In 
our opinion, these findings support consideration of the 
addition of ATLG to ciclosporin and methotrexate as a new 
standard for GVHD prophylaxis in this setting, 
and eventually comparison of it with the new GVHD 
prophylaxis platforms that are rapidly evolving—in 
particular the post-transplant cyclo phosphamide.30
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